U.S. markets close in 3 hours 59 minutes
  • S&P 500

    4,358.50
    -84.61 (-1.90%)
     
  • Dow 30

    34,360.84
    -508.53 (-1.46%)
     
  • Nasdaq

    14,585.96
    -384.01 (-2.57%)
     
  • Russell 2000

    2,242.09
    -38.91 (-1.71%)
     
  • Crude Oil

    74.78
    -0.67 (-0.89%)
     
  • Gold

    1,736.20
    -15.80 (-0.90%)
     
  • Silver

    22.43
    -0.26 (-1.14%)
     
  • EUR/USD

    1.1684
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.5200
    +0.0360 (+2.43%)
     
  • GBP/USD

    1.3534
    -0.0170 (-1.24%)
     
  • USD/JPY

    111.3440
    +0.3660 (+0.33%)
     
  • BTC-USD

    41,490.48
    -1,815.52 (-4.19%)
     
  • CMC Crypto 200

    1,025.95
    -31.20 (-2.95%)
     
  • FTSE 100

    7,028.10
    -35.30 (-0.50%)
     
  • Nikkei 225

    30,183.96
    -56.10 (-0.19%)
     

RedHill Unveils New Movantik Data For Opioid-Induced Constipation

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • RedHill Biopharma Ltd (NASDAQ: RDHL) has announced new Movantik (naloxegol) Phase 3 study data analyses.

  • The three analyses included pooled data from two Phase 3 studies involving 891 treated patients across two doses (12.5 mg and 25 mg), compared to a total of 446 patients in the placebo arms.

  • It presented the data at the PAINWeek 2021.

  • New data demonstrated rapid onset of action and sustained and predictable improvement of key symptoms associated with opioid-induced constipation (OIC) in both a subgroup of patients aged above 65 years and across both low and high-dose opioid therapy.

  • In patients aged 65 years and above, Movantik achieved significantly better response rates vs. placebo, with rapid onset of action and a higher proportion of subjects achieving spontaneous bowel movement (SBM) and complete spontaneous bowel movement (CSBM) over the first 48 hours of treatment.

  • Additional data also shows that naloxegol delivers similar rapid and sustained symptom improvement for patients, irrespective of the opioid dose.

  • Related Content: Cantor Sees 'Compelling Investment Opportunity' In This Biopharma.

  • Price Action: RDHL shares closed 5.19% lower at $9.49 on Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.